Podcasts about ARB

Hey Jeepers, it's time for another epic Jeep Talk Show flagship episode!

Articles featured in this episode: "Eastern Michigan women's lacrosse team recognized at Board of Regents meeting" - Caleb Henderson "EMU's University Park pond serves as home for dozens of koi, even during winter" - Israel Shriki "Shakespeare in the Arb brings 'The Merry Wives of Windsor' to life this summer" - Allie Beecher "EMU's online vendor change & 6 things to know about textbooks before fall 2025" - Israel Shriki

Podcasts, reviews, interviews, essays, and more at the Ancillary Review of Books.Please consider supporting ARB's Patreon!Credits:Guest: Arkady MartineTitle: 40,000 in Gehenna by C.J. CherryhHost: Jake Casella BrookinsMusic by Giselle Gabrielle GarciaArtwork by Rob PattersonOpening poem by Bhartṛhari, translated by John BroughTranscribers: Kate Dollarhyde and John WM ThompsonReferences:Vote in the Ignytes!Our episode with Archita MittraA Memory Called Empire, A Desolation Called Peace, Rose/House, "Three Faces of a Beheading"Mick Herron's Slow HorsesPip Adams' AuditionAndré Alexis's Other WorldsThomas Ha's Uncertain SonsStephen Sondheim's AssassinsCherryh's Cyteen, Downbelow Station, ForeignerWatsonian vs. Doylist readingsThe Faded Sun, Hunter of WorldsLeonard Cohen's "The Future"Theodore Sturgeon's "The Golden Helix"Internet Science Fiction Database (ISFDB)Ursula Le Guin's The Left Hand of Darkness, Rocannon's WorldJoanna Russ's The Female ManAnne McCaffrey's Dragonriders of PernSerpent's ReachAmal El-MohtarAnaïs Mitchell's HadestownEmmanuel Levinas & Martin BuberOctavia E. Butler"Third Person Intense Internal"Jane Alison's Meander, Spiral, ExplodeElizabeth BearAnn Leckie, Tamsyn Muir, Jeff VanderMeerAncillary JusticeLois McMaster BujoldSeth Dickinson's The Traitor Baru Cormorant & our episode on itMax Gladstone's Craft SequenceA Pattern LanguageDavid Brin, Vernor VingeArkady's BlueskyLouis Kahn4th Street FantasyViable ParadiseWisconWesley AndrewsThe BriarSK CoffeeBogart's DoughnutNortheast Tea HouseDreamHavenUncle Hugo'sDelany's The Jewel-Hinged Jaw and The Motion of Light in WaterCherryh's Wave Without A ShoreGreg Egan's PhoresisKathy Mar's "Forty Thousand in Gehenna" from the album "Finity's End and other Songs of the Station Trade"Wizards vs. Lesbians episode with Ann Leckie on C.J. Cherryh's Foreigner

Send us a textOn this episode of the CMAJ Podcast, hosts Dr. Mojola Omole and Dr. Blair Bigham speak with two authors of the latest “Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care”The discussion reflects a shared urgency: despite past successes, Canada's hypertension control rates are declining. The new guidelines aim to reverse this trend by simplifying diagnosis and treatment for frontline clinicians.Dr. Rémi Goupil, a nephrologist and clinician researcher at Sacré-Cœur Hospital in Montreal, and Dr. Greg Hundemer, a nephrologist and clinician scientist at The Ottawa Hospital, explain that the updated guideline is deliberately designed for primary care providers. They highlight key shifts: lowering the diagnostic threshold for hypertension to  ≥ 130/80 mm Hg, simplifying blood pressure targets, and emphasizing accurate, standardized measurement techniques both in clinic and at home. The guidelines were created with input from a majority-primary care committee—including family physicians, nurses, pharmacists, and patient partners—to ensure clinical applicability.Together, the panel outlines a streamlined nine-step treatment algorithm, emphasizing combination therapy as first-line pharmacologic management. They explain the evidence supporting ARB–thiazide combinations, discuss cost considerations for drug selection, and address adherence challenges. They also explore red flags for secondary hypertension and how the algorithm supports—but does not replace—clinical judgment.For physicians, this guideline offers a clear and practical roadmap: measure blood pressure correctly, aim for systolic pressure below 130 mm Hg, and use the simplified treatment sequence to improve adherence and outcomes. Designed to be easy to implement, the new approach aims to empower primary care providers to act with confidence.Join us as we explore medical solutions that address the urgent need to change healthcare. Reach out to us about this or any episode you hear. Or tell us about something you'd like to hear on the leading Canadian medical podcast.You can find Blair and Mojola on X @BlairBigham and @DrmojolaomoleX (in English): @CMAJ X (en français): @JAMC FacebookInstagram: @CMAJ.ca The CMAJ Podcast is produced by PodCraft Productions

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

THE LANCET 2003;362:772-776Background: Angiotensin converting enzyme inhibitors (ACEi) reduce mortality and morbidity in patients with systolic heart failure (see CONSENSUS and SOLVD trials). However, registry data showed that up to 20% of patients with systolic heart failure were not taking ACEi. One of the frequent causes for intolerance to ACEi is cough. Angiotensin converting enzyme inhibitors work by blocking the conversion of angiotensin I to angiotensin II, a key step in the renin–angiotensin–aldosterone system (RAAS). Angiotensin II receptor blockers were tolerated in patients with systolic heart failure who were intolerant to ACEi. However, data on long term effectives as an alternative to ACEi were lacking.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Alternative trial sough to assess if the angiotensin-receptor blocker (ARB) candesartan, could improve outcomes in patients with systolic heart failure who are intolerant to ACEi.Patients: Eligible patients had left ventricular ejection fraction of 40% or less and NYHA class II, III or IV symptoms of at least 4 weeks duration. Patients had also to be intolerant to ACEi.Exclusion criteria were not provided in the main manuscript.Baseline characteristics: Patients were recruited from 618 centers in 26 countries. The trial randomized 2,028 patients – 1,013 randomized to receive candesartan and 1,015 to receive placebo.The average age of patients was 67 years and 68% were men. The average left ventricular ejection fraction was 30%. Cardiomyopathy was ischemic in 68% of the patients. The NYHA class was II in 48% of the patients, III in 49% and IV in 4%.Approximately 50% had hypertension, 27% had diabetes, 61% had prior myocardial infarction, 9% had stroke, 25% had atrial fibrillation and 14% were current smokers.At the time of enrollment, 85% were taking a diuretic, 46% were taking digoxin, 55% were taking beta-blockers and 24% were taking spironolactone.The most common reasons for ACEi intolerance were cough in 72% of the patients, hypotension in 13%, renal dysfunction in 12% and angioedema or anaphylaxis in 4%.Procedures: The trial was double-blinded. Patients were assigned in a 1:1 ratio to receive candesartan starting at 4 or 8mg once daily or placebo. The treatment was doubled every two weeks to a target dose of 32mg once daily.After randomization, follow up occurred at 2, 4, and 6 weeks, 6 months and every 4 months thereafter.Endpoints: The primary outcome was a composite of cardiovascular death or heart failure hospitalizations. All deaths were classified as cardiovascular unless there was a clear non-cardiac cause.Analysis was performed based on the intention-to-treat principle. The estimated sample size to have 80% power at 5% alpha was 2,000 patients. The sample size calculation assumed 18% relative risk reduction in the primary outcome with candesartan assuming a 15% annual event rate in the placebo arm.Results: The median follow up time was 34 months. The mean candesartan daily dose was 23mg at 6 months.Candesartan reduced the primary endpoint of cardiovascular death or heart failure hospitalizations (33.0% vs 40.0%, adjusted HR: 0.70, 95% CI: 0.60 – 0.81; p< 0.001). Candesartan reduced the individual components of the primary outcome - (21.6% vs 24.8%; p= 0.02) for cardiovascular death and (20.4% vs 28.2%; p< 0.001) for heart failure hospitalizations. All-cause death was also lower with candesartan (26.2% vs 29.2%, adjusted HR: 0.83, 95% CI: 0.70–0.99; p= 0.033). The number of patients who had any hospitalization as well as the total number of hospitalizations were numerically but not statistically significantly lower with candesartan (60.2% with candesartan vs 63.3%; p= 0.16) and (1,718 vs 1,835; p= 0.06).Candesartan was associated with more hypotension (3.7% vs 0.9%), more increase in creatinine (6.1% vs 2.7%) and more hyperkalemia (1.9% vs 0.3%). Angioedema occurred in three patients in the candesartan group and none in the placebo group. Cough occurred in two patients taking candesartan and four taking placebo.Authors reported no significant subgroup interactions, however, a corresponding graph was not provided.Conclusion: In patients with systolic heart failure who are intolerant to ACEi, candesartan reduced the primary composite outcome of cardiovascular death or heart failure hospitalizations with a number needed to treat of approximately of 14 patients over 34 months of follow up. Candesartan also reduced all-cause death with a number needed to treat of approximately 33 patients. Adverse events including hypotension, increase in creatinine and hyperkalemia were more common with candesartan.The reduction in the primary endpoint with candesartan was significant and offers an alternative for patients who are unable to tolerate ACEi. Of note, 72% of the patients enrolled in the trial were intolerant to ACEi due to cough. This trial did not include a head-to-head comparison between ARBs and ACEi, and therefore does not address which agent should be preferred as first-line therapy. Only 24% of participants were receiving spironolactone. The combination of ARBs with spironolactone, may increase the risk of adverse events, particularly hyperkalemia and kidney injury.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

Ännu en gång tar sig Inga Dönare ut på fältet och denna gången till Borås för ett snack med landslagsspelare Besfort Zeneli, men det först efter att han tjafsat klart med storebrorsan. Det blir snack om framtiden, om de kluvna känslorna kring flytt kontra guldstrid med Elfsborg samt lite om lasagne och sällskapsspelet Maffia (som landslaget tydligen lirar en del).Dessutom: Gais tur till Knippla, Blåvitts bibliska provspelare, Häckens Europalottning, Janlinds besök i den Holmbergska trädgården och samtal om med BK Häcken FF-spelaren om skillnaden mellan Sverige och USA.Det och mycket mer får du i veckans avsnitt av Inga dônare, en fotbollspodd från Göteborgs-Posten.Ansvarig utgivare: Christofer Ahlqvist00:00:00 Start00:03:58 Vi kommer fram till Borås00:04:59 Elfsborgs Hall of Fame00:08:56 Gamla Ryavallen00:17:36 Vi spanar in spelare i katakomberna00:18:44 Historien om när Niklas Hult brakade in i Elfsborgs materialare00:20:00 Besfort och Arbër Zeneli00:27:02 Långintervju med Besfort Zeneli00:59:51 In med Fredrik Janlind01:01:07 Gais01:08:34 ÖIS01:12:01 IFK Göteborg01:13:40 BK Häcken herr01:15:58 BK Häcken dam Hosted on Acast. See acast.com/privacy for more information.

Podcasts, reviews, interviews, essays, and more at the Ancillary Review of Books.Please consider supporting ARB's Patreon!Credits:Guest: andré m. carringtonTitle: Death of the Author by Nnedi OkoraforHost: Jake Casella BrookinsMusic by Giselle Gabrielle GarciaArtwork by Rob PattersonOpening poem by Bhartṛhari, translated by John BroughTranscribers: Kate Dollarhyde and John WM ThompsonReferences:andré's Speculative Blackness, The Black Fantastic, and Audiofuturism (forthcoming)The Eaton ConferenceMalik Gaines & Alexandro Segade's cosmic opera Star Choir, based on the work of Octavia E. ButlerHanna Yanagahira's To ParadiseTochi Onyebuchi's Harmattan SeasonGeorge R. R. Martin's A Song of Ice and FireN.K. JemisinMichael Zapata's The Lost Book of Adana MoreauTom Hanks' That Thing You DoAndew Stanton's Wall-EBecky Chambers' Monk & RobotOlaf StapledonKim Stanley Robinson's The Ministry for the Futureandré's BlueskyAudio.futurism Instagram

El camp de futbol de Gerb es convertirà aquest dissabte en l’epicentre del jovent de la Noguera amb la celebració de la XVII Comarkalada. La Trobada Jove de la Noguera, organitzada conjuntament en aquesta ocasió per l’Associació de Joves de Gerb, l’Ajuntament de Gerb i l’Oficina Jove del Consell Comarcal de la Noguera. La temàtica de l’edició d’aquest any serà ‘Els estils musicals’, i la gresca nocturna anirà a càrrec dels grups Comandants de Tros, Kintus i el dj Jordi Laro Ferrocarrils licita les obres per a la supressió d’un pas a nivell a Gerb, a la línia Lleida-La Pobla de Segur. Es construirà un pas elevat que millorarà la seguretat viària i ferroviària al municipi. Els treballs tindran una durada de 12 mesos i s’iniciaran el primer trimestre de l’any vinent El castell de Montsoriu i el castell i col•legiata de Sant Pere d’Àger són l’eix central d’una proposta d’agermanament que estan treballant els municipis d’Arbúcies i Àger Balaguer organitza aquest divendres un tardeig amb motiu del Dia per l’alliberament LGBTI+. El tardeig començarà a dos quarts de nou amb una performance i animació a càrrec de Platanito Bello, I seguidament a Entreteles oferirà un espectacle de teles acrobàtiques Balaguer donarà el tret de sortida a la temporada de bany aquest diumenge 15 de juny amb l’obertura de les piscines municipals d’estiu. Com ja és habitual, el servei es prestarà a dos espais diferents: les piscines del Poliesportiu, que romandran obertes fins al 24 d’agost, i les del Secà, que tancaran el 7 de setembre Comença la sega del cereal a la zona del canal d’Urgell amb bones perspectives de rendiments però preus a la baixa. Les fortes calors no han afectat la producció d’ordi, però sí que hi podria haver minva al blat Acord a la UE per incrementar un 50% els aranzels sobre les importacions agrícoles de Rússia i Bielorússia. La mesura afecta productes com el sucre, el vinagre o la farina, fins ara no subjectes a drets de duana addicionals Agenda Balaguer Aquest divendres es farà a les 19:30h a la sala d’actes de la Paeria la presentació del llibre ‘Històries i cabòries’ de Miquel Aguilà L’Associació Dona Pas celebrarà dissabte el 15è Mercat del Vell. Més de quaranta paradistes es preveu que participin al mercat del Vell, una iniciativa que pretén oferir un espai per a la venda d’objectes “usats” a particulars i entitats. Es farà durant el matí al Passeig de l’Estació de Balaguer En el marc de les Jornades Europees d’Arqueologia, el Museu de la Noguera ha organitzat aquest diumenge a les 11h del matí una visita i posterior xerrada al Castell Formós de Balaguer L’Orfeó Balaguerí celebrarà el concert de cloenda del curs el pròxim diumenge a dos quarts de vuit del vespre a l’església de Sant Domènec. Un recital molt especial que comptarà amb la participació de la Coral de Binèfar, en una col•laboració que unirà més de 70 veus damunt l’escenari i que oferirà un viatge musical per èpoques i estils diversos Agenda comarca El projecte Nilak afronta el segon i últim cap de setmana d’activitats a Àger. La programació culmina amb tres propostes destacades, un d’elles participativa amb veïns i veïnes del municipi El municipi de Cubells acollirà aquest dissabte la I Trobada d’Activitat Física per a la gent gran de la Noguera, una iniciativa pionera destinada a promoure l’envelliment actiu i la vida saludable entre les persones majors de 60 anys Durant el cap de setmana tindrà lloc una nova edició de la Geodiada de Lleida, que enguany es desenvoluparà pels entorns d’Avellanes, Santa Linya, Tartareu, Vilanova de la Sal i Montclús En el marc de les Jornades Culturals 2025 organitzades per Lo Pas Nou, aquest cap de setmana tindrà lloc l’exposició “A foc lent”, una mostra d’artesania realitzada per dones de la Coma de Meià Esports El Teatre Municipal de Balaguer acollirà el proper diumenge la cloenda del curs de l’Escola i Club de Gimnàstica Rítmica amb l’espectacle Greatest CircusDescarregar àudio (42:44 min / 20 MB)

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

THE LANCET 2003;362:767-771Background: Angiotensin II which plays a role in ventricular remodeling and progression of heart failure can be produced by pathways independent of angiotensin convening enzyme. Preliminary studies showed that the combination of angiotensin II blockers with angiotensin-converting enzyme inhibitors (ACEi) improves hemodynamics and reduces ventricular remodeling.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial sough to assess if adding the angiotensin-receptor blocker (ARB), candesartan, to ACEi could improve outcomes in patients with systolic heart failure.Patients: Eligible patients had left ventricular ejection fraction of 40% or less within the previous 6 months, and NYHA class II, III or IV symptoms. Patients with NYHA class II symptoms had to have cardiac-related hospitalization within 6 months. Patients also had to have treatment with ACEi at a constant dose for at least 30 days.Exclusion criteria were not provided in the main manuscript.Baseline characteristics: Patients were recruited from 618 centers in 26 countries. The trial randomized 2,548 patients – 1,276 randomized to receive candesartan and 1,272 to receive placebo.The average age of patients was 64 years and 79% were men. The average left ventricular ejection fraction was 28%. Cardiomyopathy was ischemic in 62% of the patients. The NYHA class was II in 24% of the patients, III in 73% and IV in 3%.Approximately 48% had hypertension, 30% had diabetes, 56% had prior myocardial infarction, 9% had stroke, 27% had atrial fibrillation and 17% were current smokers.At the time of enrollment, 90% were taking a diuretic, 58% were taking digoxin, 55% were taking beta-blockers, 17% were taking spironolactone and all but two patients were taking ACEi.Procedures: The trial was double-blinded. Patients were assigned in a 1:1 ratio to receive candesartan starting at 4 or 8mg once daily or placebo. The treatment was doubled every two weeks to a target dose of 32mg once daily.After randomization, follow up occurred at 2, 4, and 6 weeks, 6 months and every 4 months thereafter.Endpoints: The primary outcome was a composite of cardiovascular death or heart failure hospitalizations. All deaths were classified as cardiovascular unless there was a clear non-cardiac cause.Analysis was performed based on the intention-to-treat principle. The estimated sample size to have 80% power at 5% alpha was 2,300 patients. The sample size calculation assumed 16% relative risk reduction in the primary outcome with candesartan assuming an 18% annual event rate in the placebo arm.Results: The median follow up time was 41 months. The mean candesartan daily dose was 24mg at 6 months.Candesartan reduced the primary endpoint of cardiovascular death or heart failure hospitalizations (37.9% vs 42.3%, adjusted HR: 0.85, 95% CI: 0.75 – 0.96; p= 0.01). Candesartan reduced the individual components of the primary outcome - (23.7% vs 27.3%; p= 0.021) for cardiovascular death and (24.2% vs 28.0%; p= 0.018) for heart failure hospitalizations. There was no significant reduction in all-cause death (29.5% with candesartan vs 32.4%; p= 0.105). The number of patients who had any hospitalization was similar in both groups (66.8% with candesartan vs 67.5%; p= 0.7), however, the total number of hospitalizations was lower with candesartan (2,462 vs 2,798; p= 0.023).Serum creatinine at least doubled in 7% of the patients in the candesartan group vs 6% in the placebo group. In the subset of patients taking spironolactone, serum creatinine at least double in 11% of the patients taking candesartan compared to 4% of the patients taking placebo.Hyperkalemia, defined as serum potassium of 6 mmol/L or higher, occurred in 3% of the patients in the candesartan group vs 1% in the placebo group. In the subset of patients taking spironolactone, hyperkalemia occurred in 4% of the patients taking candesartan compared to 1% of the patients taking placebo.There were two cases of angioedema in the candesartan group and three in the placebo group. All patients were taking an ACEi.There were no significant subgroup interactions, including in patients taking both beta-blockers and ACEi at baseline.Conclusion: In patients with systolic heart failure, adding candesartan to an ACEi reduced the primary composite outcome of cardiovascular death or heart failure hospitalizations with a number needed to treat of approximately of 23 patients over 41 months of follow up. The total number of all-cause hospitalizations was reduced by 336 with candesartan. All-cause death was not significantly reduced with candesartan.While the results of the trial appear impressive, the high number of adverse outcomes with candesartan in patients taking spironolactone is concerning. Spironolactone led to significant reduction in all-cause mortality in patients with systolic heart failure, as seen in the RALES trial, and should be prioritized over adding candesartan. Notably, fewer than 20% of patients in the trial were on spironolactone at baseline; if more had been, the incremental benefit of candesartan would likely have been reduced due to an increased risk of adverse effects from triple neurohormonal blockade (ACEi, ARBs, and mineralocorticoid receptor antagonists). Furthermore, spironolactone acts by blocking the aldosterone receptor, which is downstream in the renin–angiotensin–aldosterone system. Since candesartan blocks angiotensin II upstream in the same pathway, simultaneous inhibition at multiple points may lead to diminishing benefit.Finally, the differences observed in the subgroup of patients on beta-blockers between this trial and Val-HeFT remain unclear and may simply reflect the play of chance. As we previously discussed, patients receiving both an ACEi and beta-blockers had worse outcomes with valsartan in the Val-HeFT trial.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

Podcasts, reviews, interviews, essays, and more at the Ancillary Review of Books.Please consider supporting ARB's Patreon!Credits:Guest: Roseanna PendleburyTitles: The 2025 Hugo Novel & Novella ListHost: Jake Casella BrookinsMusic by Giselle Gabrielle GarciaArtwork by Rob PattersonOpening poem by Bhartṛhari, translated by John BroughTranscribers: Kate Dollarhyde and John WM ThompsonReferences:Hugo Novella Finalists:The Brides of High Hill by Nghi VoThe Butcher of the Forest by Premee MohamedNavigational Entanglements by Aliette de BodardThe Practice, the Horizon, and the Chain by Sofia SamatarThe Tusks of Extinction by Ray NaylerWhat Feasts at Night by T. KingfisherHugo Novel Finalists:Alien Clay by Adrian TchaikovskyThe Ministry of Time by Kaliane BradleyService Model by Adrian TchaikovskySomeone You Can Build a Nest In by John WiswellA Sorceress Comes to Call by T. KingfisherThe Tainted Cup by Robert Jackson BennettThe Clarke Award listPaul Kincaid's CoulorfieldsRoseanna's “A Path Through the Landscape” for A Reader of Else, plus Paul Kincaid's “The Books That Made Me” for Through the dark labyrinthNnedi Okorafor's BintiCasella's idea of a Hugo for Best Translated WorkRenay's Hugo Spreadsheet of DoomAlex Jeffers's A Mourning CoatLorraine Wilson's Last to DrownThe Ursula K. Le Guin PrizeThe Ignyte AwardsPremee Mohamed's The Siege of Burning GrassVajra Chandraskera's RakesfallJared Pechaček's The West PassageSeth Dickinson's Exordia and The Traitor Baru CormorantEmet North's In UniversesEden Robin's Remember You Will DieScott Guild's PlasticAliya Whiteley's Three Eight OneT. Kingfisher's Saint of Steel booksMarie Brennan's A Natural History of DragonsRobert Jackson Bennett's Divine Cities and Founders trilogiesAdrian Tchaikovsky's House of Open WoundsGreg EganCharlie Stross's Neptune's BroodZachary Gillan's “Reading Weird Fiction in an Age of Fascism”Foz Meadow's A Strange and Stubborn EnduranceRoseanna's review of Someone To Build A Nest InBrad Wright's TravelersHelen MacDonald and Sin Blaché's ProphetRoseanna's Small Press Dispatch columnNerds of a Feather

I ftuar në “Live From Tirana” me Ronaldo Sharkën, ka qenë Arbër Xhihani, ekspert punësimi. Ai ka folur më shumë për lidhjen që eksizton mes turizmit dhe punësimit, si dhe çfarë problematikash ka ky sektor…

In this episode, we discuss the diagnosis and treatment of resistant hypertension, including a newer endothelin receptor antagonist (ERA) called aprocitentan (Tryvio®). Key Concepts The diagnosis of true resistant hypertension is based on requiring more than 3 antihypertensives (ACE inhibitor or ARB + calcium channel blocker + diuretic) to achieve goal BP, ruling out inaccurate BP readings, and ensuring patient adherence to their antihypertensive therapy. Non-pharmacologic therapy (especially dietary sodium restriction), medication adherence, and lifestyle changes are critical to the treatment of resistant hypertension. The preferred 4th line option for most patients with resistant hypertension is spironolactone. After adding spironolactone, additional therapies are based on expert opinion and patient-specific factors. These additional therapies may include beta blockers, alpha-2 agonists, alpha-1 blockers, hydralazine, minoxidil, and aprocitentan. References Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72(5):e53-e90. doi:10.1161/HYP.0000000000000084 Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

Irbesartan is an angiotensin II receptor blocker (ARB) used primarily for the management of hypertension and diabetic nephropathy in type 2 diabetes. It selectively inhibits the binding of angiotensin II to the AT1 receptor found in vascular smooth muscle and the adrenal gland. This blockade results in vasodilation, reduced aldosterone secretion, decreased sodium and water retention, and ultimately lower blood pressure. Irbesartan is administered orally, with a typical starting dose of 150 mg once daily, which may be increased to 300 mg depending on the patient's clinical response and tolerability. Adverse effects of irbesartan are generally mild but can include hyperkalemia and dizziness. Hypotension may occur, especially in volume-depleted individuals or those on diuretics. Routine monitoring of renal function and serum potassium is recommended, especially in patients with underlying kidney disease or those taking potassium-sparing agents or supplements. Irbesartan is contraindicated in pregnancy due to the risk of fetal toxicity and should be discontinued as soon as pregnancy is detected.

Lancet 1999;353:2001-07Background: Beta-blockers directly reduce cardiac contractility and myocardial oxygen demand. For decades, they were avoided in patients with acute and chronic heart failure over concerns they would facilitate decompensation of the condition. The therapeutic cornerstones of treatment, prior to the modern era of clinical trials, focused on managing symptoms and quality of life with diuretics and inotropic agents like digoxin; however, new paradigms were arising that focused on addressing neurohormonal mechanisms of chronic disease that were over-activated in the failing heart. The first major success came with inhibition of the renin angiotensin aldosterone system with angiotensin converting enzyme inhibitors whose effect on mortality for patients with mild and severe forms of chronic heart failure were demonstrated in the V-HEFT II, CONSENSUS, and SOLVD trials. Additional benefits were demonstrated with the mineralocorticoid receptor antagonist spironolactone in the RALES trial. These drug classes primarily work by reducing afterload and volume retention. Appreciating why they work for improving cardiac performance and managing symptoms in heart failure patients is straightforward when we consider the major factors that effect cardiac stroke volume - preload, afterload and contractility; however, it is also noteworthy the effects these agents have on sudden death. How beta-blockade benefits the failing heart is less obvious (outside prevention of sudden death). Mechanistic studies in patients with chronic heart failure have consistently shown that when beta blockers are used for more than 1 month, left ventricular function improves. Beta blocker therapy appears to restore the density of beta-adrenergic receptors after they have been downregulated by the chronic overactivity of the sympathetic nervous system. The first major placebo-controlled RCT to demonstrate a mortality benefit used the non-selective beta blocker carvedilol. The trial was small and not originally designed to test mortality and was stopped early without clearly predefined stopping rules. Furthermore, 8% of total patients selected for participation in the trial were excluded prior to randomization after a 2 week, open-label run-in phase with the study drug, which saw 2% of all patients experience worsening heart failure or death representing 24 patients (the difference in total deaths between groups was 9 when the trial was stopped). The Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) was the first large scale trial designed to test the hypothesis that beta-blockade with metoprolol controlled/extended release (CR/XL) added to optimum medical therapy reduces mortality in patients with chronic systolic heart failure.Patients: Patients were recruited from 313 sites in 13 European countries and the United States. Eligible patients were men and women between the age of 40 to 80 years with symptomatic heart failure (NYHA class II-IV) for >/= 3 months before randomization. They had to be on a diuretic and ACE inhibitor for at least 2 weeks. Other drugs, including digoxin, could also be used. Patients also had to have an EF of /=68 beats per minute.Patients were excluded if: they had an MI or unstable angina within 28 days; had an indication or contraindication for treatment with beta-blocker; beta blockade within 6 weeks; heart failure due to systemic disease (i.e., amyloidosis) or alcohol abuse; scheduled or performed cardiac transplant; an ICD; procedures such as CABG or PCI planned or performed in the past 4 months; 2nd or 3rd degree AV block unless a pacemaker was present; unstable or decompensated heart failure defined by pulmonary edema or hypoperfusion or supine systolic BP 25% deviation of the number of observed versus expected consumed placebo tablets during the run-in period.Baseline characteristics: The mean age of patients was 64 years and approximately 78% were male. Slightly more than 30% of patients were above the age of 70. The average EF was 28%. The average SBP was 130 mmHg and heart rate was 82 bpm. Most patients had mild to moderate heart failure, with 41% in NYHA Class II, 56% in Class III, and only 3% in Class IV. Ischemic cardiomyopathy accounted for 65% of cases and nonischemic causes accounted for 35%. Most patients were on an ACE inhibitor or ARB (95%) and diuretic (90%). Digoxin was used in 63%. Trial procedures: Prior to randomization, the study was preceded by a single-blind, 2-week placebo run-in period. Patients meeting eligibility were then randomized to placebo or metoprolol CR/XL. The starting dose of placebo or metoprolol CR/XL was 12.5 mg daily for patients in NYHA class III or IV and 25 mg daily for patients in NYHA class II. The dose was doubled every 2 weeks until the target dose of 200 mg daily was reached. Patients were followed every 3 months.Endpoints: The primary outcome was all-cause mortality. It was estimated that 3,200 patients would need to be followed for 2.4 years to detect a 30% relative reduction in mortality based on annual mortality rate of 9.4% in the placebo group. This would achieve at least 80% power with a 2-sided alpha of 0.04. Patients were recruited faster then planned and so the final sample size of 3,991 patients increased the power of the study.The study was monitored by an independent safety committee and predefined stopping rules for efficacy were based on all-cause mortality, done when 25%, 50%, and 75% of expected deaths had occurred. Results: The trial was stopped early after the 2nd preplanned interim analysis when 50% of expected deaths had occurred. The mean duration of follow-up at the time of stopping was 1 year. The mean daily dose of metoprolol CR/XL was 159 mg once daily, with 87% receiving 100 mg or more and 64% receiving the target dose of 200 mg daily. In the placebo group, the corresponding values were 179 mg daily, 91% and 82%. The study drug was discontinued permanently in 14% of patients in the metoprolol group and 15% in the placebo group. Six months after randomization, heart rate decreased by 14 bpm in the metoprolol group compared to only 3 bpm in the placebo group. Systolic blood pressure decreased less in the metoprolol group (-2.1 vs 3.5 mmHg).Compared to placebo, metoprolol significantly reduced all-cause mortality (7.3% vs 10.8%; RR 0.66; 95% CI 0.53—0.81). Cardiovascular mortality accounted for 91% of all deaths; with sudden death accounting for 58% and death from worsening heart failure accounting for 24% of all deaths. All 3 of these causes of death were significantly reduced by metoprolol. The relative and absolute effects on death were greatest for patients with NYHA class III heart failure.Conclusions: In this trial of stable patients with mild to moderate chronic systolic heart failure, who were optimized on an ACEi or ARB and diuretic, metoprolol CR/XL significantly reduced all-cause mortality. Approximately 30 patients would need to be treated with metoprolol compared to placebo for 1 year to prevent 1 death. This trial represents a significant win for beta blockade in patients with chronic systolic heart failure. While the NNT in this trial is slightly higher than in SOLVD, it is important to appreciate that follow-up time in SOLVD was more than 3x longer. Limitations to external validity in this trial include the run-in period and stringent inclusion and exclusion criteria. Our enthusiasm is also tempered by early stopping, which has been found to be associated with false positive or exaggerated results but this concern is mitigated to some extent in this trial because the rules for early stopping were clearly defined in the protocol.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

Podcasts, reviews, interviews, essays, and more at the Ancillary Review of Books.Please consider supporting ARB's Patreon!Credits:Guest: Maia Gil′AdíTitle: The Lost Book of Adana Moreau by Michael ZapataHost: Jake Casella BrookinsMusic by Giselle Gabrielle GarciaArtwork by Rob PattersonOpening poem by Bhartṛhari, translated by John BroughReferences:Palgrave SFF: A New CanonThe Zombie ArchiveDoom Patterns: Latinx Speculations and the Aesthetics of ViolenceAugustina Bazterrica's Tender is the FleshFernanda Trias' Pink SlimeKazuo Ishiguro's Never Let Me GoColson Whitehead's Zone OneToni Morrison's BelovedFernanda Melchor's Hurricane SeasonIndrapramit DasBrendan Shay Basham's Swim Home to the Vanished & Casella's reviewMariana Enriquez's Our Share of NightFredric JamesonChicago Review of Books AwardsIlana Masad's “Holocaust Beach Reads” for The Maris ReviewJason (Friday the 13th)Simón BolívarAugust Derleth, Clark Ashton Smith, H.P. Lovecraft, C.L. MooreMoebius/Jean GiraudAncient AliensBlake Crouch's Dark Matter & adaptationStuds TerkelUS Occupation of the Dominican Republic, 1916Junot Diaz's The Brief Wondrous Life of Oscar WaoJonbar pointsAimee Pokwatka's Self-Portrait with NothingLavie Tidhar's The Circumference of the Earth & Unholy LandRob Nixon's Slow Violence and the Environmentalism of the PoorSesshu Foster's Atomic AztecsMaia on Bluesky

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

Bitcoin is rallying as U.S. President Donald Trump urges Americans to “go out and buy stocks now” and renews pressure on Federal Reserve Chair Jerome Powell to cut interest rates. Ethereum has also awakened this time.~This episode is sponsored by Tangem~Tangem ➜ https://bit.ly/TangemPBNUse Code: "PBN" for Additional Discounts!Guest: Tim Warren, Host of Investing BrozInvesting Broz Youtube ➜ ‪‪https://www.youtube.com/@investingbrozFollow on Twitter ➜ @tims_ta  00:00 Intro00:18 Sponsor: Tangem01:10 Trump: Better buy now01:39 $BTC analysis07:02 Tariffs: beginning of the end?10:26 Bitcoin Dominance topped?12:35 $ETH analysis14:30 ETH end of year prediction18:50 $UNI analysis22:38 $ARB analysis26:20 $SUI analysis29:38 $AVAX analysis32:08 CNBC: Apple & Google Apocalypse (Virtuals incoming)33:40 $VIRTUAL analysis36:35 Outro#Crypto #Bitcoin #Ethereum~Ethereum Leads Altcoin Rally! Technical Analysis w/ @investingbroz  ~⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺⎺Join our community! Diamond Circle (FREE): https://www.paulbarronnetwork.com/storeForge Membership: https://www.paulbarronnetwork.com/forge-membershipPrivate Telegram Group (FREE): https://t.me/+nISqoMxrok40NTcxSubscribe on YouTube ✅ https://bit.ly/PBNYoutubeSubscribeTwitter

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

Cada setmana Joana Serra de la Llibreria Catalana de Perpinyà ens tria un llibre. Avui ens ha portat Història Galàctica del Porró, de Salvador García-Arbós (Vibop Edicions).

Podcasts, reviews, interviews, essays, and more at the Ancillary Review of Books.Please consider supporting ARB's Patreon!Credits:Guest: Sean McTiernanTitle: Dreams of Amputation by Gary J. ShipleyHost: Jake Casella BrookinsMusic by Giselle Gabrielle GarciaArtwork by Rob PattersonOpening poem by Bhartṛhari, translated by John BroughTranscribers: Kate DollarhydeReferences:The SFUltra podcastAlasdair Gray's Lanark & Poor ThingsJames Joyce's UlyssesFredric JamesonAbsolute DC comicsMichael Comeau's HellbertaAlan Grant & John Wagner's DoomlordRay Nayler's Where the Axe is BuriedNeil Sharpson's When The Sparrow FallsMichael Mann's BlackhatLater Die HardsTony Scott's Enemy of the StateJean BaudrillardShipley's Stratagem of the Corpse, Crypt(o)spasm, and Serial Killing: A Philosophical AnthologyDennis CooperBlake Butler's “Sci-Fi Doesn't Have to Be Dominated by Horny Bro Wizards” for ViceDarko SuvinManuela Draeger's Kree (and Antoine Volodine's other work)Mark DanielewskiB.R. YeagerApocalypse PartyWilliam S. Burrough's Naked LunchNeal StephensonDaniel DennettMemeticsPhilip K. Dick's A Scanner DarklyJ.G. Ballard, M. John Harrison, John UpdikeBlake Butler's Uxa.gov & the SFUltra episodeChristopher Priest's “Hull 0, Scunthorpe 3”Brian Evenson, Pierre GuyotatHarrison's Nova SwingTad Williams' OtherlandDerek Raymond (Rober Cook)'s He Died With His Eyes OpenThomas Metzinger The Ego TunnelBernard Wolfe's LimboEvenson's Last Days / Brotherhood of MutilationWilliam Gibson, Bruce SterlingWarhammer 40kBallard's CrashCurt Siodmak's Donovan's BrainMatt from BookpilledNick LandCCRU & Dark EnlightenmentBaudrillard's The Transparency of Evil, Cool Memories, The Perfect CrimeMark Fisher, Kodwu Eshun, Kode9Fisher's “Exiting the Vampire Castle”Andrea DworkinBrion GysinTravis Baldree's Legends and LattesWalter Hill's The DriverBrian CatlingIan SinclairSFUltra episodes on Lanark, Poor Things, and Catling

In this episode, Cherise is joined by returning guests John Gentry, AIA, Partner and Co-founder, and Aimee O'Carroll, ARB, Partner and Co-founder of Go'C in Seattle, Washington. They discuss the new Alton Wines Tasting Room and Wine Garden in Walla Walla, Washington.You can see the project here as you listen along.Alton Wines is quietly tucked into a natural cove just outside Walla Walla, where wave-like hills and vineyards shape the land. The site—once considered “unfarmable” due to its position and soil—offered a rare opportunity: to build something that would not disrupt the landscape, but instead belong to it. As guests arrive, the architecture guides them southward along a vine-covered arbor made of a steel frame that leads directly to the heart of the experience: a tasting room and wine garden arranged across the site from east to west. If you enjoy this episode, visit arcat.com/podcast for more. If you're a frequent listener of Detailed, you might enjoy similar content at Gābl Media. Mentioned in this episode:ARCATemy

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

Podcasts, reviews, interviews, essays, and more at the Ancillary Review of Books.Please consider supporting ARB's Patreon!Credits:Guest: Christian P. HainesTitles: The Moon is a Harsh Mistress by Robert A. Heinlein, and The Terraformers by Annalee Newitz Host: Jake Casella BrookinsMusic by Giselle Gabrielle GarciaArtwork by Rob PattersonOpening poem by Bhartṛhari, translated by John BroughTranscriber: Kate DollarhydeReferences:Stephen King's The Shining and CarrieRafael Bernal's His Name Was DeathMichel Nieva's Dengue BoyDaryl Gregory's When We Were RealAdrian Tchaikovsky's Service Model, Christian's review for ARBIo9Our Opinions Are CorrectHeinlein's Starship TroopersChristian's The Terraformers review for LARBNewitz's AutonomousHeinlein's Farmer in the Sky, The Rolling StonesArcherMilton FriedmanOrwell's 1984Rand's Atlas ShruggedJames S.A. Corey's The ExpanseKim Stanley Robinson's Mars TrilogyUrsula K. Le Guin's The DispossessedIan McDonald's New Moon trilogyFrank Herbert's DuneSamuel R. Delany's Babel-17Le Guin's The Left Hand of DarknessJo Walton's Among Others and our episode on itHolly Jean Buck's After Geoengineering"Engineering Swallows Up Politics"Neal Stephenson's Termination ShockKSR's AuroraMcKenzie Wark's Molecular RedUlrich Haarbürste's Roy Orbison Wrapped in ClingfilmStar Trek's “Infinite Diversity in Infinite Combinations”Spinoza's idea of conatusWalter Kaufman's introduction to Martin Buber's I and ThouKant's Categorical ImperativeAbbot ElementaryDelany's Trouble On TritonOctavia E. Butler's Parable of the TalentsMarx's CapitalJohn Brunner's Stand on ZanzibarKohei Sato's Slow Down: The Degrowth ManifestoKSR's The Ministry for the Future, New York 2140Le Guin's The Word for World is ForestGamers with GlassesFive Theses on Antifascist Game Criticism

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

I ftuar në “Live Frpm Tirana” me Ronaldo Sharkën, ka qenë Arbër Xhihani, ekspert punësimi. Kush janë sot profesionet më të paguara sipas tij?

Podcasts, reviews, interviews, essays, and more at the Ancillary Review of Books.Please consider supporting ARB's Patreon!Credits:Guest: Marita ArvanitiTitle: Lud-in-the-Mist by Hope MirrleesHost: Jake Casella BrookinsMusic by Giselle Gabrielle GarciaArtwork by Rob PattersonOpening poem by Bhartṛhari, translated by John BroughReferences:A Meal of Thorns and the Ancillary Review of Books are Hugo finalists! We are delighted and honored; a big congratulations to all the finalists.Dianna Wynne Jones, Greer Gilman, Elizabeth BearDianna Wynne Jones' Fire and HemlockElizabeth Hand's Mortal LovePamela Dean's Tam LinTerri Windling & Ellen Datlow edited fairytale collectionsRobin Hobb's Mad Ship Patrick O'Brian's Aubrey-Maturin booksAmal El-Mohtar's The River Has RootsRobert Jackson Bennett's A Drop of CorruptionE.R. EddisonLaurie J. Marks' Elemental Logic seriesKatherine Arden's The Bear and the NightingaleEuripedes' The BacchaeFriedrich Nietzsche's The Birth of TragedyMichael Swanwick's Hope in the MistJ.R.R. Tolkien's The Hobbit & The Lord of the RingsC.S. Lewis's The Chronicles of Narnia, specifically Prince CaspianRobert Luketic's Legally BlondeEdgar Allen Poe, Julio Cortázar, Franz Kafka, H.P. LovecraftUrsula K. Le Guin's The Farthest ShoreAnne Carson's translation of BakkhaiChristina Rossetti's Goblin MarketSusanna Clarke's Jonathan Strange & Mr NorrellFritz Lang's MetropolisN.K. Jemisin's The Hundred Thousand KingdomsSofia Samatar's Olondrian novelsSylvia Townsend Warner's Lolly WillowesNaomi Mitchison's To the Chapel Perilous and Memoirs of a SpacewomanT.H. White, Tanith LeeEllen Kushner's Thomas the RhymerJo Walton's Among OthersKat Howard's Roses and RotElizabeth Hand's Waking the MoonTerri Windling's The Wood WifeGuardian Article on romantasyCopyright romantasy caseSarah J. MaasJacqueline Carey Kushiel's DartNicholas Stuart Gray's Seven SwansMarita's Instagram

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

What is the strategy for Authentic Restaurant Brands' newest acquisition?This week's episode of the Restaurant Business podcast A Deeper Dive features Alex Macedo, the CEO of the multi-brand operator Authentic Restaurant Brands (ARB). The company recently acquired the New England polished casual-dining concept Tavern in the Square, its latest in a series of deals for largely regional chains. The company owns Pollo Tropical, Primanti Bros., P.J. Whelihan's and Mambo Seafood. The company's chains generate $1 billion worth of revenue and $150 million in EBITDA, or earnings before interest, taxes, depreciation and amortization. We asked Alex why Tavern in the Square fits with these companies, when it plans to buy another chain and what's the strategy behind acquiring regional concepts. We also asked Alex about ARB's ultimate exit strategy. Check it out.

Podcasts, reviews, interviews, essays, and more at the Ancillary Review of Books.Please consider supporting ARB's Patreon!Credits:Guest: Archita MittraTitle: Among Others by Jo WaltonHost: Jake Casella BrookinsMusic by Giselle Gabrielle GarciaArtwork by Rob PattersonOpening poem by Bhartṛhari, translated by John BroughReferences:Eliza Chan's Fathomfolk & Archita's reviewSue Lynn Tan's ImmortalLavanya Lakshminarayan's Interstellar Megachef & The Ten Percent ThiefMichael Nieva's Dengue BoyIsaac Fellman's Notes from a RegicideUrsula K. Le Guin's The Lathe of HeavenErnest Cline's Ready Player OneStranger ThingsJ.R.R. Tolkien's The Lord of the RingsJame Tiptree, Jr.Samuel R. Delany's Babel-17List of books mentioned in Among OthersAnne Rice Vampire ChroniclesC.S. Lewis's Chronicles of NarniaLe Guin's “Why Are Americans Afraid of Dragons?” from The Language of the NightKurt Vonnegut's Cat's CradleLe Guin's The Dispossessed and Delany's Trouble on TritonWalton's Informal History of the HugosC.J. Cherryh's Gate of IvrelArchita's reviews @ Strange Horizons & LocusArchita on Twitter, Bluesky, InstagramArchita's Locus year-endCasella's Locus year-endJared Pechaček's The West Passage, Casella's review, and of course Jared's A Meal of Thorns episode on E.R. Eddison's Mistress of Mistress

Një emision ku si asnjëherë më parë mendimet dhe fjalët vijnë si në jetë, të pacensuruara…Mirë, ndoshta pak të censuruara. “Pardon my French” nga Jonida Alickolli, të cilës i bashkohet në moderim Arbër Çepani, ku e vetmja gjë që nuk dinë të bëjnë është të flasin frengjisht! Surpriza e këtij sezoni është Lei Kraja. Moderatorja i bashkohet dyshes sonë dhe një gjë është e sigurtë, të qeshurat dhe surprizat janë të garantuara.

durée : 00:18:20 - Les Midis de Culture - par : Marie Labory - Les critiques discutent de deux bandes dessinées : "Bouquet de peur", un album qui interroge les angoisses de son auteur Nando van Arb et "Le retour" d'Antoine Cossé, un conte fantastique qui aborde le traumatisme de la Première Guerre mondiale avec beaucoup de douceur. - réalisation : Laurence Malonda - invités : Lucie Servin Journaliste, spécialiste de littérature et de bande dessinée; Victor Macé de Lépinay Journaliste

durée : 00:27:20 - Les Midis de Culture - par : Marie Labory - Trois bandes dessinées sont à l'honneur du débat critique : "Billy Lavigne" d'Anthony Pastor, "Bouquet de peur" de Nando Van Arb et "Le retour" d'Antoine Cossé. - réalisation : Laurence Malonda - invités : Lucie Servin Journaliste, spécialiste de littérature et de bande dessinée; Victor Macé de Lépinay Journaliste

durée : 00:07:00 - Les Midis de Culture - par : Marie Labory - Les critiques discutent de deux bandes dessinées : "Bouquet de peur", un album qui interroge les angoisses de son auteur Nando van Arb et "Le retour" d'Antoine Cossé, un conte fantastique qui aborde le traumatisme de la Première Guerre mondiale avec beaucoup de douceur. - réalisation : Laurence Malonda - invités : Lucie Servin Journaliste, spécialiste de littérature et de bande dessinée; Victor Macé de Lépinay Journaliste

Të ftuar në “Pardon My French” me Jonida Aliçkolli dhe Arbër Çepani kanë qenë Niko Komani dhe Paloma, për të diskutuar dhe për të komentuar dinamikat e ndodhura gjatë 24 orëve të fundit. Për efektet e këtij formati të gjithë kanë diçka për të thënë, si ata që e shijojnë e argëtohen, por edhe ata që janë kundër. Por, të gjithë janë dakord në një pikë: “Big Brother” nuk lë askënd indiferent.

Clearstream will launch crypto custody and settlement services, aligning with EU regulations. Offchain Labs plans to buy ARB tokens for Arbitrum's treasury. El Salvador and Paraguay signed a crypto regulatory pact. Leveraged ETF trading on MicroStrategy surged amid stock declines. Mt. Gox moved $905M in BTC, sparking speculation on creditor repayments.RESOURCEShttps://www.bloomberg.com/news/articles/2025-03-11/deutsche-boerse-s-clearstream-to-offer-bitcoin-ether-custody?embedded-checkout=truehttps://www.theblock.co/post/345602/offchain-labs-arbitrum-token?utm_source=rss&utm_medium=rsshttps://www.coindesk.com/policy/2025/03/10/el-salvador-signs-crypto-regulation-agreement-with-paraguayhttps://www.coindesk.com/markets/2025/03/11/leveraged-etfs-tied-to-strategy-see-trading-volume-surge-as-bitcoin-hodler-mstr-teeters-on-200-day-averagehttps://www.theblock.co/post/345589/mt-gox-moves-905-million-worth-of-bitcoin-to-unmarked-wallet-address-arkham?utm_source=rss&utm_medium=rssSecure your Business & Digital Life with Cyber Strategy Institute https://www.thegrowmeco.com/course/https://cyberstrategyinstitute.com/warden/ https://csi-store.samcart.com/products/wardenguard-personal-1device-annual/?coupon=DCN_Warden WHERE TO FIND DCNDailyCryptoNews.Net https://twitter.com/DCNDailyCrypto Trader Cobb X: @TraderCobbEditing Services https://www.contentbuck.com——————————————————————***NOT FINANCIAL, LEGAL, OR TAX ADVICE! JUST OPINION! I AM NOT AN EXPERT! I DO NOT GUARANTEE A PARTICULAR OUTCOME I HAVE NO INSIDE KNOWLEDGE! YOU NEED TO DO YOUR OWN RESEARCH AND MAKE YOUR OWN DECISIONS! THIS IS JUST EDUCATION & ENTERTAINMENT! ©Copyright 2024 Matthew Aaron Podcasts LLCDaily Bitcoin, Ethereum, & Crypto News! Hosted on Acast. See acast.com/privacy for more information.

Podcasts, reviews, interviews, essays, and more at the Ancillary Review of Books.Please consider supporting ARB's Patreon!Credits:Guest: Dan HartlandTitle: Heir to the Empire by Timothy ZahnHost: Jake Casella BrookinsMusic by Giselle Gabrielle GarciaArtwork by Rob PattersonOpening poem by Bhartṛhari, translated by John BroughReferences:Gautam Bhatia's The SentenceAlex Pheby's WaterblackCristina Rivera Garza's The Taiga SyndromeKatherine Addison's The Tomb of DragonsElizabeth Sandifer's Hugboxing vs ScabpickingDavid BrinThe Wilhelm ScreamJack London's The Call of the WildBrandon Taylor's “against casting tape fiction”The idea of “novelization style” as discussed in Garth Marenghi's DarkplaceI saw your black chanel boots mr skywalkerTimothy Zahn's Cascade PointDiane Carey's Ghost ShipWinamp skinsMichael P. Kube-McDowell's Black Fleet Crisis trilogyVonda N. McIntyre's The Crystal StarUna McCormackKevin J. AndersonMichael A. Stackpole's I, JediDresden CodakKim Stanley Robinson's 2312AndorDr. Who "New Adventures" novelsAhsoka, RebelsAlan Dean Foster's Splinter of the Mind's EyeTales from Mos Eisley Cantina and Tales from Jabba's PalaceStrange Horizons Criticism Special Issue & Tansy Gardam's article on Jackson's LOTR filmsThe Going Rogue episode on The Star Wars Holiday Special

N Engl J Med 2019;381:1411-1421Background Percutaneous coronary intervention (PCI) had been clearly established as the standard of care for ST elevation myocardial infarction. Yet many patients taken for PCI have multiple lesions in addition to the culprit. The benefit of routinely treating additional significant lesions has been unclear, with previous smaller trials showing reductions in composite outcomes primarily driven by reduced revascularization rates.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The COMPLETE (Complete vs Culprit-Only Revascularization Strategies to Treat Multivessel Disease after Early PCI for STEMI) trial investigated whether performing percutaneous coronary intervention (PCI) on non-culprit lesions reduces cardiovascular risk in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease.Patients The trial enrolled 4,041 patients from 140 centers in 31 countries between February 2013 and March 2017. Eligible patients had STEMI with successful culprit-lesion PCI and at least one non-culprit coronary artery lesion with ≥70% stenosis (or 50-69% stenosis with FFR ≤0.80) in a vessel ≥2.5mm in diameter. Patients were randomized within 72 hours after successful culprit-lesion PCI. Exclusion criteria included planned surgical revascularization and previous coronary bypass surgery.Baseline Characteristics The mean age was approximately 62 years, with about 80% being male. Approximately 19% had diabetes, 8% had previous MI, and 7% had previous PCI. Over 90% of patients underwent primary PCI (vs. pharmacoinvasive or rescue PCI), with 80% using radial access.The groups were well-balanced, with similar SYNTAX scores at baseline and similar culprit and non-culprit lesion characteristics. About 76% had one residual diseased vessel and 24% had two or more. Guideline directed medical therapy was robust and balanced, including more than 99% on dual antiplatelet therapy, 98% on statins, 88% on beta blocker, and 85% on ACEi or ARB.In patients in the complete revascularization group designated for non-culprit PCI during index hospitalization, the mean time to PCI was 1 day. In the group designated for non-culprit PCI after discharge, the mean time was 23 days.Trial procedures Patients were randomized to complete revascularization (n=2,016) or culprit-lesion-only PCI (n=2,025). In the complete revascularization group, investigators specified before randomization whether non-culprit PCI would occur during index hospitalization or after discharge (within 45 days).Everolimus-eluting stents were recommended for all procedures. Both groups received guideline-based medical therapy including dual antiplatelet therapy with aspirin and ticagrelor for at least one year.Endpoints The first coprimary outcome was cardiovascular death or new myocardial infarction. The second coprimary outcome was cardiovascular death, myocardial infarction, or ischemia-driven revascularization. Secondary outcomes included individual components of the composite outcomes, all-cause mortality, and safety outcomes like major bleeding, stroke, and stent thrombosis.Trialists estimated that a sample of 4000 patients would give 80% power to detect a 22% lower risk of the composite of cardiovascular death or myocardial infarction in the complete-revascularization group than in the culprit-lesion-only PCI group, assuming an event rate of 5% per year in the culprit-lesion-only PCI group. The first coprimary outcome was tested at a P value of 0.045 and the second at a P value of 0.0119.The co-primary endpoints were analyzed according to the time to first event approach. Confidence intervals for secondary and exploratory efficacy outcomes were not adjusted for multiple comparisons, and therefore inferences drawn from these intervals may not be reproducible.Results Over a median follow-up of 36.2 months, the first coprimary outcome occurred in 7.8% of the complete-revascularization group versus 10.5% of the culprit-lesion-only group (hazard ratio 0.74, 95% CI: 0.60-0.91; p= 0.004). Benefit was driven by reduced myocardial infarction rates (5.4% vs 7.9%) while cardiovascular death rates were similar (2.9% vs 3.2%).The second coprimary outcome was also reduced with complete revascularization (8.9% versus 16.7%, HR: 0.51, 95% CI: 0.43-0.61; p

Today's sponsor is Freed AI! Freed's AI medical scribe listens, transcribes, and writes notes for you. Over 15,000 healthcare professionals use Freed and you should too! Learn more here! Clopidogrel (Plavix) is an antiplatelet medication. You need to understand the pharmacokinetics of clopidogrel and how CYP2C19 affects this medication. Doxycycline is a tetracycline antibiotic. Calcium, iron, and other metal cations can bind doxycycline and reduce the absorption of the medication. Hyzaar is a combination of losartan and hydrochlorothiazide. Losartan is an ARB and hydrochlorothiazide is a thiazide diuretic. Kytril (granisetron) is an antiemetic medication. It is from the same class of medication as the more commonly used ondansetron. Restoril (temazepam) is a benzodiazepine. It is primarily used to treat insomnia as it has a much shorter half-life than many of the other benzodiazepines.

In this episode of The Band of Traders, Kyle, Baba Yaga, Bear Goes Long, and special guest Jeff (2yrflipper) break down the realities of prop trading, market edges, and why fixed income trading is becoming a lost art. Jeff shares insights into his work with TradeFundrr, where he's building a stable of serious traders and helping them transition from simulated accounts to live trading backed by T3.The conversation dives into risk management, why most traders misunderstand reward-to-risk ratios, and the critical role of discipline in scaling up. 2yrflipper also opens up about his evolving trading style, the challenges of modern bond markets, and why mastering spreads and roll trading remains one of the few lasting edges. Packed with valuable lessons and raw trading wisdom, this episode is a must-listen for anyone navigating the world of prop trading and market structure.2yrflipper's Tradefundrr Link: https://checkout.tradefundrr.com/products?aff=2yrflipper2yrflipper's Discord Link: https://discord.gg/3KDZRWKTENSponsors and FriendsOur podcast is sponsored by Sue Maki at Fairway Independent Mortgage (MLS# 206048). Licensed in 38 states, if you need anything mortgage-related, reach out to her at SMaki@fairwaymc.com or give her a call at (520) 977-7904. Tell her 2 Bulls sent you to get the best rates available!For anyone trading futures, check out Vantatrading.com. Founded by Mr. W Banks and Baba Yaga, they provide a ton of educational content with the focus of teaching aspiring traders how to build a repeatable, profitable process. You can find our exclusive affiliate link/discount code for Vanta ‘s subscription in our free discord server as well!If you are interested in signing up with TRADEPRO Academy, you can use our affiliate link here. We receive compensation for any purchases made when using this link, so it's a great way to support the show and learn at the same time! **Join our Discord for a link and code to save 10%**Visit Airsoftmaster.com to support one of our own!To contact us, you can email us directly at bandoftraderspodcast@gmail.com Be sure to follow us on Facebook, Twitter, or Discord to get updated when new content is posted! Check out our directory for other amazing interviews we've done in the past!If you like our show, please let us know by rating and subscribing on your platform of choice!If you like our show and hate social media, then please tell all your friends!If you have no friends and hate social media and you just want to give us money for advertising to help you find more friends, then you can donate to support the show here!Jeff (2yrflipper):Two years after leaving his position as an ARB clerk in the corn futures market, 2yrflipper found himself deeply entrenched in the world of bond trading. His journey took a significant turn when he became one of the early adopters of trading technology, wielding one of the first handheld devices in the trading pit. Despite acknowledging his limitations as a pit trader, his connection with Chip Kenyon, a prominent figure in the bond pit, paved the way for a remarkable opportunity. For the following two years, he immersed himself in trading a staggering volume of contracts on Chip's behalf, gaining invaluable insights into the intricacies of the trading screen that has fueled a long and successful trading careerFollow on TwitterOther PodcastsBaba Yaga:Solving problems, helping set goals, and refining processes is the bulk of Baba's passion. He does that in many contexts ranging from nonprofits to real estate firms and everything in between. He focuses on market structure through the lens of TPO charting and executes based on volume, misplaced large orders, and delta. He loves the opening range breakout and typically trades the market from the “inside out”. Vanta Trading websiteVanta Trading YouTubeFollow Baba Yaga on TwitterBear:Bear made the transition from investing to trading at the beginning of COVID. After initial success with options, he quickly learned that his luck was greater than his skill and shifted his focus to futures. Bear has fully embraced the role of emotions and mental capital with the mindset that trading futures is purely an internal struggle that rewards patience, calm, bravery, focus, passion, and commitment. Beyond markets Bear finds joy in his community as a volunteer firefighter and EMT.Follow Bear on TwitterAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

We're back, after a brief hiatus! Today we talk about duration of therapy for bacteremia, Factor XI inhibition for atrial fibrillation, whether to stop ACEi or ARB before elective surgery, and whether GLP-1 agonists are beneficial in heart failure with preserved ejection fraction. Go to minute 7:30 to skip the banter. 7 vs 14 Days of Antibiotics for Bacteremia (BALANCE)Abelacimab vs Rivaroxaban for Atrial Fibrillation (AZALEA-TIMI-71)Asenduxian vs Apixaban for Atrial Fibrillation (OCEANIC-AF)ACEi or ARB Discontinuation Before Surgery (STOP or NOT)Tirzepatide for HFpEF and Obesity (SUMMIT)Music from Uppbeat (free for Creators!):https://uppbeat.io/t/soundroll/dopeLicense code: NP8HLP5WKGKXFW2R

Today's sponsor is Freed AI! Freed's AI medical scribe listens, transcribes, and writes notes for you. Over 15,000 healthcare professionals use Freed and you should too! Learn more here! On this episode of the Top 200 Drugs Podcast, I cover medications 146-150. This podcast includes; sevelamer, dalteparin, sertraline, clonazepam, and irbesartan. Sevelamer is a phosphate binder that is used to treat hyperphosphatemia in patients with chronic kidney disease. Dalteparin is a low molecular weight heparin product that is used to prevent and treat blood clots. Sertraline is a commonly used SSRI that can be helpful in managing depression and anxiety. Clonazepam is a benzodiazepine that can be used for acute relief of anxiety. Sedation, confusion, and fall risk are potential adverse effects. Irbesartan is an ARB that can be used for hypertension. Hyperkalemia and angioedema are two adverse effects to be aware of.